8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1, 2008

VAXGEN, INC.
(Exact name of registrant as specified in its charter)

DELAWARE	0-26483	94-3236309
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CALIFORNIA	94080
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (650) 624-1000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 1—REGISTRANT’S BUSINESS AND OPERATIONS

Item 1.01. Entry into a Material Definitive Agreement.

Note Repurchase Agreements

On July 1, 2008, VaxGen Inc. (“VaxGen”) entered into a Note Repurchase Agreement (the “Alexandra Agreement”) with Alexandra Global Master Fund Ltd. (“Alexandra”), as amended on July 7, 2008 (the “Amendment”), whereby VaxGen agreed to repurchase two of its 5 1/2% convertible senior subordinated notes due April 2010 (“Notes”) in an aggregate principal amount of $11,000,000 at a purchase price of $9,020,000, plus accrued interest of $163,013.35, based on an assumed settlement date of July 8, 2008.

On July 3, 2008, VaxGen entered into Note Repurchase Agreements with Whitebox Convertible Arbitrage Partners, LP (the “Whitebox Agreement”) and Guggenheim Portfolio Company XXXI, LLC (the “Guggenheim Agreement”). Pursuant to the Whitebox Agreement, VaxGen agreed to repurchase its Notes in the principal amount of $8,350,000 at a purchase price of $6,847,000, plus accrued interest of $123,741.93, based on an assumed settlement date of July 8, 2008. Pursuant to the Guggenheim Agreement, VaxGen agreed to repurchase its Note in the principal amount of $650,000 at a purchase price of $533,000, plus accrued interest of $9,633.07, based on an assumed settlement date of July 8, 2008.

VaxGen has not initiated any broader effort to repurchase or restructure its remaining Notes.

The Alexandra Agreement, the Amendment, the Whitebox Agreement, and the Guggenheim Agreement are attached to this report as Exhibit 10.1, 10.2, 10.3, and 10.4, respectively (the “Agreements”). The foregoing descriptions are qualified in their entirety by reference to the full text of the Agreements.

Item 9.01. Financial Statements and Exhibits.

Exhibit
Number	Description
10.1	Note Repurchase Agreement, dated July 1, 2008, by and between VaxGen, Inc. and Alexandra Global Master Fund Ltd.
10.2	Amendment No. 1 to Note Repurchase Agreement, dated July 7, 2008 by and between Alexandra Global Master Fund Ltd. and VaxGen, Inc.
10.3	Note Repurchase Agreement, dated July 3, 2008, by and between VaxGen, Inc. and Whitebox Convertible Arbitrage Partners, LP
10.4	Note Repurchase Agreement, dated July 3, 2008, by and between VaxGen, Inc. and Guggenheim Portfolio Company XXXI, LLC

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VaxGen, Inc.
(Registrant)

Dated: July 8, 2008

By: /s/                                                                           
James P. Panek
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit
Number	Description
10.1	Note Repurchase Agreement, dated July 1, 2008, by and between VaxGen, Inc. and Alexandra Global Master Fund Ltd.
10.2	Amendment No. 1 to Note Repurchase Agreement, dated July 7, 2008 by and between Alexandra Global Master Fund Ltd. and VaxGen, Inc.
10.3	Note Repurchase Agreement, dated July 3, 2008, by and between VaxGen, Inc. and Whitebox Convertible Arbitrage Partners, LP
10.4	Note Repurchase Agreement, dated July 3, 2008, by and between VaxGen, Inc. and Guggenheim Portfolio Company XXXI, LLC

EX-10.1

Exhibit 10.1

NOTE REPURCHASE AGREEMENT

THIS NOTE REPURCHASE AGREEMENT (this “Agreement”) to repurchase VaxGen, Inc. 5¹/2% Convertible Senior Subordinated Notes Due April 1, 2010 is made as of July 1, 2008, by and between Alexandra Global Master Fund Ltd., a British Virgin Islands International Business Company (“Holder”), on the one hand, and VaxGen, Inc., a Delaware corporation (“Company”), on the other hand.

W I T N E S S E T H:

WHEREAS, the Holder is the owner and holder of those certain 5¹/2% Convertible Senior Subordinated Notes Due April 1, 2010 (the “Notes”) identified on Schedule A hereto, issued under an Indenture, dated as of April 5, 2005 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the “Trustee”);

WHEREAS, the Notes, to date, have not matured; and

WHEREAS, the Holder, desiring to sell the Notes, approached the Company with respect thereto, and the Company in turn desires to repurchase the Notes.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Holder and the Company hereby agree as follows:

1. Sale of Notes. Subject to the terms and conditions of this Agreement, the Company agrees to purchase from the Holder, and the Holder agree to sell to the Company, the Notes identified on Schedule A hereto, in the aggregate principal amount and for an aggregate purchase price set forth on Schedule A hereto. The purchase and sale of the Notes shall take place at the offices of Cooley Godward Kronish, 3175 Hanover Street, Palo Alto, California 94304 at 9:00 A.M. (local time), on July 8, 2008 (which time and place are designated as the “Closing” and the date thereof the “Settlement Date”). At the Closing, the Holder shall deliver to the Company the Notes, duly endorsed or accompanied by an assignment duly endorsed and in a form acceptable to the Trustee, against payment of the aggregate purchase price described on Schedule A hereto (the “Purchase Price”), by wire transfer in the amounts and using the wire transfer instructions to be provided separately to the Company by Holder. Upon receipt by the Holder of the Purchase Price, the Company shall become the legal and beneficial owner of the Notes and of all rights and interest therein or related thereto and to the monies due and to become due under the terms of the Notes. The Holder hereby agrees that upon receipt of the Purchase Price, the Notes shall be cancelled and the Company shall have no further obligation to the Holder thereunder.

2. Representations and Warranties of the Holder. The Holder hereby represents and warrants to the Company with respect to the Notes issued to such Holder that:

2.1 Ownership of Notes. The Holder has, and at the Closing will have, good and marketable right, title and interest (legal and beneficial) in and to the Notes, free and clear of all liens, pledges, security interests, charges, contractual obligations, claims or encumbrances of any kind. Upon payment for the Notes in accordance with this Agreement, the Holder will convey the Notes to the Company free and clear of all liens, pledges, security interests, charges, contractual obligations, claims or encumbrances of any kind.

2.2 Organization; Authorization. The Holder has full power and authority to enter into this Agreement. The execution, delivery and performance by the Holder of this Agreement has been duly authorized by all requisite action by the Holder and this Agreement constitutes a valid and binding obligation of the Holder, enforceable against the Holder in accordance with its terms, except as enforcement may be limited by general principles of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally.

2.3 No Consent Required. No consent, authorization, approval, order, license, certificate or permit or act of or from, or declaration or filing with, any foreign, federal, state, local or other governmental authority or regulatory body or any court or other tribunal or any party to any contract, agreement, instrument, lease or license to which the Holder is a party, is required for the execution, delivery or performance by the Holder of this Agreement or any of the other agreements, instruments and documents being or to be executed and delivered hereunder or in connection herewith or for the consummation of the transactions contemplated hereby.

2.4 Disclosure of Information. The Holder has received all the information it considers necessary or appropriate to determine whether to sell the Notes to the Company pursuant to this Agreement. The Holder acknowledges (i) the Company has not made any representation or warranty, express or implied, except as set forth herein, regarding any aspect of the sale and purchase of the Notes, the operation or financial condition of the Company or the value of the Notes, (ii) that it is not relying upon the Company in making its decision to sell the Notes to the Company pursuant to this Agreement and (iii) that the Company is relying upon the truth of the representations and warranties in this Section 2 in connection with the purchase of the Notes hereunder.

2.5 Tax Consequences. The Holder has had an opportunity to review the federal, state and local tax consequences of the sale of the Notes to the Company and the transactions contemplated by this Agreement with its own tax advisors. The Holder is relying solely on such advisors and not on any statements or representations of the Company.

2.6 No Conflict. Neither the execution and delivery of this Agreement or the consummation of any of the transactions contemplated hereby nor compliance with or fulfillment of the terms, conditions and provisions hereof or thereof will conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default (with or without notice or lapse of time, or both), or an event creating rights of acceleration, termination or cancellation or a loss of rights under (i) any material note, instrument, agreement, mortgage, lease, license, franchise, permit or other authorization, right, restriction or obligation to which the Holder is a party or by which the Holder or any of its properties is bound, (ii) any judgment or decree applicable to, or affecting, the Holder or (iii) any statute, law or rule to which the Holder is subject.

-2-

2.7 No Solicitation. The Holder has made no general solicitation in connection with the sale of the Notes, acknowledges that it independently approached the Company regarding the transactions contemplated hereby and that the Company did not initiate or attempt to initiate the transactions contemplated hereby.

3. Representations and Warranties of the Company. The Company hereby represents and warrants to the Holder that:

3.1 Organization; Authorization. The Company has full power and authority to enter into this Agreement. The execution, delivery and performance by the Company of this Agreement has been duly authorized by all requisite action by the Company and this Agreement constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement may be limited by general principles of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally.

3.2 No Consent Required. No consent, authorization, approval, order, license, certificate or permit or act of or from, or declaration or filing with, any foreign, federal, state, local or other governmental authority or regulatory body or any court or other tribunal or any party to any contract, agreement, instrument, lease or license to which the Company is a party, is required for the execution, delivery or performance by the Company of this Agreement or any of the other agreements, instruments and documents being or to be executed and delivered hereunder or in connection herewith or for the consummation of the transactions contemplated hereby.

3.3 No Conflict. Neither the execution and delivery of this Agreement or the consummation of any of the transactions contemplated hereby nor compliance with or fulfillment of the terms, conditions and provisions hereof or thereof will conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default (with or without notice or lapse of time, or both), or an event creating rights of acceleration, termination or cancellation or a loss of rights under (i) any material note, instrument, agreement, mortgage, lease, license, franchise, permit or other authorization, right, restriction or obligation to which the Company is a party or by which the Company or any of its properties is bound, (ii) any judgment or decree applicable to, or affecting, the Company or (iii) any statute, law or rule to which the Company is subject.

3.4 No Litigation. There is no action, suit, proceeding, judgment, claim or investigation pending or, to the knowledge of the Company, threatened against the Company which could reasonably be expected in any manner to challenge or seek to prevent, enjoin, alter or materially delay any of the transactions contemplated by this Agreement.

4. Securities Act; Transfer Restrictions. The Company hereby acknowledges that the (i) securities are not registered pursuant to the Securities Act of 1933, as amended, and (ii) the Notes and the common stock underlying the Notes may only be disposed of in compliance with Federal and State securities laws.

-3-

5. Miscellaneous.

5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York, without regard to its choice of law provisions. The parties hereto hereby agree that any action brought under this Agreement or related to the transactions contemplated hereby shall be brought in a Federal or State court located in the County of San Francisco in the State of California.

5.2 Counterparts. This Agreement may be executed in two or more counterparts and by facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

5.3 Publicity. The Holder will use reasonable commercial efforts to keep the terms and existence of this transaction confidential, provided that the Holder may share the details of this transaction in confidence with its attorneys, investors and financial and tax advisors, and may advise other potential purchasers of the Notes that the Notes have been repurchased by the Company. The Holder shall not be prohibited from referring communications with any other party regarding the transactions contemplated hereby to the Company.

5.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

5.5 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during the normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally-recognized overnight courier, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 5.5).

5.6 Amendment and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of Holder and the Company.

5.7 Further Assurances. Each party hereby agrees to execute any additional documents and take any additional actions as may be reasonably necessary to carry out the terms of this Agreement.

-4-

5.8 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

5.9 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein.

[signature page follows]

-5-

IN WITNESS WHEREOF, the Holder and the Company have executed this Agreement effective as of the date and year first above written.

ALEXANDRA GLOBAL MASTER
FUND LTD.

By: ALEXANDRA INVESTMENT
MANAGEMENT, LLC, as
Investment Advisor

By:	/s/ Mikhail Filimonov
	Name: Mikhail Filimonov Title: Chairman and Chief Executive Officer

Address for notices:

Alexandra Global Master Fund Ltd.
c/o Alexandra Investment Management, LLC
767 Third Avenue
39^th Floor
New York, New York 10017

Phone No: (212) 301-1800
Facsimile No.: (212) 301-1810

VAXGEN, INC.

By:	/s/ James P. Panek
	Name: James P. Panek Title: President and Chief Executive Officer

Address for notices:

VaxGen, Inc.
349 Oyster Point Boulevard
South San Francisco, CA 94080
Attn: Mr. James Panek
Facsimile No.: (650) 624-1001

-6-

SCHEDULE A
to
Note Repurchase Agreement
dated as of July 1, 2008
by and between
ALEXANDRA GLOBAL MASTER FUND LTD.
and
VAXGEN, INC.

Title of Securities: 5 1/2% Convertible Senior Subordinated Notes due April 1 2010 (the “Notes”)

Aggregate Principal Amount of Notes: $11,000,000.00

Purchase Price: $820 for each $1,000 principal amount of Notes plus accrued and unpaid interest thereon to the Settlement Date.

Accrued Interest: $163,013.88 plus an additional $1,680.56 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties.

Aggregate Purchase Price: $9,183,013.88 plus an additional $1,680.56 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties.

Settlement Date: July 8, 2008

-7-

EX-10.2

Exhibit 10.2

AMENDMENT NO. 1

TO

NOTE REPURCHASE AGREEMENT

This Amendment No. 1 to certain provisions of that Note Repurchase Agreement dated as of July 1, 2008 by and between Alexandra Global Master Fund Ltd., a British Virgin Islands International Business Company (“Holder”), on the one hand, and VaxGen, Inc., a Delaware corporation (“Company”), on the other hand, is effective as of this 7th day of July, 2008 (the “Amendment”).

Amendment of Note Repurchase Agreement

Whereas, the undersigned are parties to that certain Note Repurchase Agreement, dated July 1, 2008 (the “Agreement”);

Whereas, the Holder and the Company wish to amend certain provisions of, and Schedule A to, the Agreement; and

Whereas, pursuant to Section 5.6 of the Agreement, any term of the Agreement may be amended, and the observance of any term of the Agreement waived (either generally or in a particular instance and either retroactively or prospectively), by written consent of Holder and the Company.

Now, Therefore, the undersigned agree as follows:

AGREEMENT

1. Amendment.

1.1 Section 1. Section 1 of the Agreement is hereby amended and restated to read in its entirety as follows:

“1. Sale of Notes. Subject to the terms and conditions of this Agreement, the Company agrees to purchase from the Holder, and the Holder agree to sell to the Company, the Notes identified on Schedule A hereto, in the aggregate principal amount and for an aggregate purchase price set forth on Schedule A hereto. The purchase and sale of the Notes shall take place at one or more closings, at the time and place and on the dates indicated on Schedule A hereto (which time and place are designated as the “Closing” and the dates thereof each, a “Settlement Date”). At the Closing, the Holder shall deliver to the Company the Notes, duly endorsed or accompanied by an assignment duly endorsed and in a form acceptable to the Trustee, against payment of the aggregate purchase price described on Schedule A hereto (the “Purchase Price”), by wire transfer in the amounts and using the wire transfer instructions to be provided separately to the Company by Holder. Upon receipt by the Holder of the Purchase Price, the Company shall become the legal and beneficial owner of the Notes and of all rights and interest therein or related thereto and to the monies due and to become due under the terms of the Notes. The Holder hereby agrees that upon receipt of the Purchase Price, the Notes shall be cancelled and the Company shall have no further obligation to the Holder thereunder.”

1.2 Schedule A. Schedule A to the Agreement is hereby amended and restated to read in its entirety as set forth on Exhibit A hereto.

2. Full Force and Effect. All other provisions of the Agreement shall remain in full force and effect.

3. Construction. This Amendment shall be construed in accordance with the laws of the State of New York, without regard to its choice of law provisions.

[Remainder of page intentionally left blank.]

In Witness Whereof, the undersigned have executed this Amendment as of the date set forth above.

ALEXANDRA GLOBAL MASTER FUND LTD.		VAXGEN, INC.
By: ALEXANDRA INVESTMENT
MANAGEMENT, LLC, as		By:	/s/ James P. Panek
Investment Advisor			Name: James P. Panek
			Title: President and Chief Executive Officer
By:	/s/ Mikhail Filimonov
	Name: Mikhail Filimonov	Address for notices:
	Title: Chairman and Chief Executive Officer
		VaxGen, Inc.
		349 Oyster Point Boulevard
Address for notices:		South San Francisco, CA 94080
		Attn: Mr. James Panek
Alexandra Global Master Fund Ltd.		Facsimile No.: (650) 624-4785
c/o Alexandra Investment Management, LLC
767 Third Avenue
39th Floor
New York, New York 10017
Phone No: (212) 301-1800
Facsimile No.: (212) 301-1810

Exhibit A

SCHEDULE A
to
Note Repurchase Agreement
dated as of July 1, 2008
by and between
ALEXANDRA GLOBAL MASTER FUND LTD.
and
VAXGEN, INC.

Title of Securities: 5 1/2% Convertible Senior Subordinated Notes due April 1 2010 (the “Notes” and each, a “Note”)

Aggregate Principal Amount of Note: $7,500,000

Purchase Price: $6,150,000 ($820 for each $1,000 principal amount of Notes) plus accrued and unpaid interest thereon to the Settlement Date.

Accrued Interest: $111,145.51 plus an additional $1,145.83 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties; provided, however, that the parties hereby agree that if the Settlement Date is extended to a date later than July 8, 2008 as a result of Holder being unable to deliver the applicable Note to the Company or its counsel on or before the Closing on the Settlement Date, no additional interest shall accrue after such Settlement Date with respect to such applicable Note.

Aggregate Purchase Price: $6,261,145.51 plus an additional $1,145.83 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties; provided, however, that the parties hereby agree that if the Settlement Date is extended to a date later than July 8, 2008 as a result of Holder being unable to deliver the applicable Note to the Company or its counsel on or before the Closing on the Settlement Date, no additional interest shall accrue after such Settlement Date with respect to such applicable Note.

Closing: Offices of Cooley Godward Kronish, 3175 Hanover Street, Palo Alto, California 94304 at 9:00 A.M. (local time), on July 8, 2008 or such later date as Holder and the Company shall mutually determine.

Settlement Date: July 8, 2008.

Aggregate Principal Amount of Note: $3,500,000

Purchase Price: $2,870,000 ($820 for each $1,000 principal amount of Notes) plus accrued and unpaid interest thereon to the Settlement Date.

Accrued Interest: $51,867.84 plus an additional $534.72 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties; provided, however, that the parties hereby agree that if the Settlement Date is extended to a date later than July 8, 2008 as a result of Holder being unable to deliver the applicable Note to the Company or its counsel on or before the Closing on the Settlement Date, no additional interest shall accrue after such Settlement Date with respect to such applicable Note.

Aggregate Purchase Price: $2,921,867.84 plus an additional $534.72 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties; provided, however, that the parties hereby agree that if the Settlement Date is extended to a date later than July 8, 2008 as a result of Holder being unable to deliver the applicable Note to the Company or its counsel on or before the Closing on the Settlement Date, no additional interest shall accrue after such Settlement Date with respect to such applicable Note.

Closing: Offices of Cooley Godward Kronish, 3175 Hanover Street, Palo Alto, California 94304 at 9:00 A.M. (local time), on July 8, 2008 or such later date as Holder and the Company shall mutually determine.

Settlement Date: July 8, 2008, or such later date as Holder and the Company shall mutually determine.

EX-10.3

Exhibit 10.3

NOTE REPURCHASE AGREEMENT

THIS NOTE REPURCHASE AGREEMENT (this “Agreement”) to repurchase VaxGen, Inc. 5¹/2% Convertible Senior Subordinated Notes Due April 1, 2010 is made as of July 3, 2008, by and between Whitebox Convertible Arbitrage Partners, LP, a BVI corporation (“Holder”), on the one hand, and VaxGen, Inc., a Delaware corporation (“Company”), on the other hand.

W I T N E S S E T H:

WHEREAS, the Holder is the owner and holder of that certain 5¹/2% Convertible Senior Subordinated Note Due April 1, 2010 (the “Note”) identified on Schedule A hereto, issued under an Indenture, dated as of April 5, 2005 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the “Trustee”);

WHEREAS, the Note, to date, has not matured; and

WHEREAS, the Holder, desiring to sell the Note, approached the Company with respect thereto, and the Company in turn desires to repurchase the Note.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Holder and the Company hereby agree as follows:

1. Sale of Note. Subject to the terms and conditions of this Agreement, the Company agrees to purchase from the Holder, and the Holder agree to sell to the Company, the Note identified on Schedule A hereto, in the principal amount and for an aggregate purchase price set forth on Schedule A hereto. The purchase and sale of the Note shall take place at the offices of Cooley Godward Kronish, 3175 Hanover Street, Palo Alto, California 94304 at 9:00 A.M. (local time), on July 8, 2008 (which time and place are designated as the “Closing” and the date thereof the “Settlement Date”). At the Closing, the Holder shall deliver to the Company the Note, duly endorsed or accompanied by an assignment duly endorsed and in a form acceptable to the Trustee, against payment of the aggregate purchase price described on Schedule A hereto (the “Purchase Price”), by wire transfer in the amounts and using the wire transfer instructions to be provided separately to the Company by Holder. Upon receipt by the Holder of the Purchase Price, the Company shall become the legal and beneficial owner of the Note and of all rights and interest therein or related thereto and to the monies due and to become due under the terms of the Note. The Holder hereby agrees that upon receipt of the Purchase Price, the Note shall be cancelled and the Company shall have no further obligation to the Holder thereunder.

2. Representations and Warranties of the Holder. The Holder hereby represents and warrants to the Company with respect to the Note issued to such Holder that:

2.1 Ownership of Note. The Holder has, and at the Closing will have, good and marketable right, title and interest (legal and beneficial) in and to the Note, free and clear of all liens, pledges, security interests, charges, contractual obligations, claims or encumbrances of any kind. Upon payment for the Note in accordance with this Agreement, the Holder will convey the Note to the Company free and clear of all liens, pledges, security interests, charges, contractual obligations, claims or encumbrances of any kind.

2.2 Organization; Authorization. The Holder has full power and authority to enter into this Agreement. The execution, delivery and performance by the Holder of this Agreement has been duly authorized by all requisite action by the Holder and this Agreement constitutes a valid and binding obligation of the Holder, enforceable against the Holder in accordance with its terms, except as enforcement may be limited by general principles of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally.

2.3 No Consent Required. No consent, authorization, approval, order, license, certificate or permit or act of or from, or declaration or filing with, any foreign, federal, state, local or other governmental authority or regulatory body or any court or other tribunal or any party to any contract, agreement, instrument, lease or license to which the Holder is a party, is required for the execution, delivery or performance by the Holder of this Agreement or any of the other agreements, instruments and documents being or to be executed and delivered hereunder or in connection herewith or for the consummation of the transactions contemplated hereby.

2.4 Disclosure of Information. The Holder has received all the information it considers necessary or appropriate to determine whether to sell the Note to the Company pursuant to this Agreement. The Holder acknowledges (i) the Company has not made any representation or warranty, express or implied, except as set forth herein, regarding any aspect of the sale and purchase of the Note, the operation or financial condition of the Company or the value of the Note, (ii) that it is not relying upon the Company in making its decision to sell the Note to the Company pursuant to this Agreement and (iii) that the Company is relying upon the truth of the representations and warranties in this Section 2 in connection with the purchase of the Note hereunder.

2.5 Tax Consequences. The Holder has had an opportunity to review the federal, state and local tax consequences of the sale of the Note to the Company and the transactions contemplated by this Agreement with its own tax advisors. The Holder is relying solely on such advisors and not on any statements or representations of the Company.

2.6 No Conflict. Neither the execution and delivery of this Agreement or the consummation of any of the transactions contemplated hereby nor compliance with or fulfillment of the terms, conditions and provisions hereof or thereof will conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default (with or without notice or lapse of time, or both), or an event creating rights of acceleration, termination or cancellation or a loss of rights under (i) any material note, instrument, agreement, mortgage, lease, license, franchise, permit or other authorization, right, restriction or obligation to which the Holder is a party or by which the Holder or any of its properties is bound, (ii) any judgment or decree applicable to, or affecting, the Holder or (iii) any statute, law or rule to which the Holder is subject.

-2-

2.7 No Solicitation. The Holder has made no general solicitation in connection with the sale of the Note, acknowledges that it independently approached the Company regarding the transactions contemplated hereby and that the Company did not initiate or attempt to initiate the transactions contemplated hereby.

3. Representations and Warranties of the Company. The Company hereby represents and warrants to the Holder that:

3.1 Organization; Authorization. The Company has full power and authority to enter into this Agreement. The execution, delivery and performance by the Company of this Agreement has been duly authorized by all requisite action by the Company and this Agreement constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement may be limited by general principles of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally.

3.2 No Consent Required. No consent, authorization, approval, order, license, certificate or permit or act of or from, or declaration or filing with, any foreign, federal, state, local or other governmental authority or regulatory body or any court or other tribunal or any party to any contract, agreement, instrument, lease or license to which the Company is a party, is required for the execution, delivery or performance by the Company of this Agreement or any of the other agreements, instruments and documents being or to be executed and delivered hereunder or in connection herewith or for the consummation of the transactions contemplated hereby.

3.3 No Conflict. Neither the execution and delivery of this Agreement or the consummation of any of the transactions contemplated hereby nor compliance with or fulfillment of the terms, conditions and provisions hereof or thereof will conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default (with or without notice or lapse of time, or both), or an event creating rights of acceleration, termination or cancellation or a loss of rights under (i) any material note, instrument, agreement, mortgage, lease, license, franchise, permit or other authorization, right, restriction or obligation to which the Company is a party or by which the Company or any of its properties is bound, (ii) any judgment or decree applicable to, or affecting, the Company or (iii) any statute, law or rule to which the Company is subject.

3.4 No Litigation. There is no action, suit, proceeding, judgment, claim or investigation pending or, to the knowledge of the Company, threatened against the Company which could reasonably be expected in any manner to challenge or seek to prevent, enjoin, alter or materially delay any of the transactions contemplated by this Agreement.

4. Securities Act; Transfer Restrictions. The Company hereby acknowledges that the (i) securities are not registered pursuant to the Securities Act of 1933, as amended, and (ii) the Note and the common stock underlying the Note may only be disposed of in compliance with Federal and State securities laws.

-3-

5. Miscellaneous.

5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York, without regard to its choice of law provisions. The parties hereto hereby agree that any action brought under this Agreement or related to the transactions contemplated hereby shall be brought in a Federal or State court located in the County of San Francisco in the State of California.

5.2 Counterparts. This Agreement may be executed in two or more counterparts and by facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

5.3 Publicity. The Holder will use reasonable commercial efforts to keep the terms and existence of this transaction confidential, provided that the Holder may share the details of this transaction in confidence with its attorneys, investors and financial and tax advisors, and may advise other potential purchasers of the Note that the Note has been repurchased by the Company. The Holder shall not be prohibited from referring communications with any other party regarding the transactions contemplated hereby to the Company.

5.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

5.5 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during the normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally-recognized overnight courier, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 5.5).

5.6 Amendment and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of Holder and the Company.

5.7 Further Assurances. Each party hereby agrees to execute any additional documents and take any additional actions as may be reasonably necessary to carry out the terms of this Agreement.

5.8 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

-4-

5.9 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein.

[signature page follows]

-5-

IN WITNESS WHEREOF, the Holder and the Company have executed this Agreement effective as of the date and year first above written.

WHITEBOX CONVERTIBLE ARBITRAGE PARTNERS, LP

By:	/s/ Jonathan Wood
	Name:	Whitebox Convertible Arbitrage Partners LP
	Title:	Whitebox Convertible Arbitrage Advisors LLC
		Whitebox Advisors LLC
		Jonathan Wood, Chief Operating Officer/Director

Address for notices:

Whitebox Convertible Arbitrage Partners, LP
3033 Excelsior Blvd, Suite 300
Minneapolis, MN 55416

Phone No: 612-253-6001
Facsimile No.: 612-253-6151

VAXGEN, INC.

By:	/s/ James P. Panek          7/3/08
	Name:	James P. Panek
	Title:	President and Chief Executive Officer

Address for notices:

VaxGen, Inc.
349 Oyster Point Boulevard
South San Francisco, CA 94080
Attn: Mr. James Panek
Facsimile No.: (650) 624-4785

-6-

SCHEDULE A

Title of Securities: 5 1/2% Convertible Senior Subordinated Notes due April 1 2010 (the “Notes”)

Principal Amount of Notes: $8,350,000

Purchase Price: $6,847,000 ($820 for each $1,000 principal amount of Notes), plus accrued and unpaid interest thereon to the Settlement Date.

Accrued Interest: $123,741.93 plus an additional $1,275.69 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties.

Aggregate Purchase Price: $6,970,741.93 plus an additional $1,275.69 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties.

Settlement Date: July 8, 2008

-7-

EX-10.4

Exhibit 10.4

NOTE REPURCHASE AGREEMENT

THIS NOTE REPURCHASE AGREEMENT (this “Agreement”) to repurchase VaxGen, Inc. 5¹/2% Convertible Senior Subordinated Notes Due April 1, 2010 is made as of July 3, 2008, by and between Guggenheim Portfolio Company XXXI, LLC, a Delaware limited liability company (“Holder”), on the one hand, and VaxGen, Inc., a Delaware corporation (“Company”), on the other hand.

W I T N E S S E T H:

WHEREAS, the Holder is the owner and holder of that certain 5¹/2% Convertible Senior Subordinated Note Due April 1, 2010 (the “Note”) identified on Schedule A hereto, issued under an Indenture, dated as of April 5, 2005 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the “Trustee”);

WHEREAS, the Note, to date, has not matured; and

WHEREAS, the Holder, desiring to sell the Note, approached the Company with respect thereto, and the Company in turn desires to repurchase the Note.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Holder and the Company hereby agree as follows:

1. Sale of Note. Subject to the terms and conditions of this Agreement, the Company agrees to purchase from the Holder, and the Holder agree to sell to the Company, the Note identified on Schedule A hereto, in the principal amount and for an aggregate purchase price set forth on Schedule A hereto. The purchase and sale of the Note shall take place at the offices of Cooley Godward Kronish, 3175 Hanover Street, Palo Alto, California 94304 at 9:00 A.M. (local time), on July 8, 2008 (which time and place are designated as the “Closing” and the date thereof the “Settlement Date”). At the Closing, the Holder shall deliver to the Company the Note, duly endorsed or accompanied by an assignment duly endorsed and in a form acceptable to the Trustee, against payment of the aggregate purchase price described on Schedule A hereto (the “Purchase Price”), by wire transfer in the amounts and using the wire transfer instructions to be provided separately to the Company by Holder. Upon receipt by the Holder of the Purchase Price, the Company shall become the legal and beneficial owner of the Note and of all rights and interest therein or related thereto and to the monies due and to become due under the terms of the Note. The Holder hereby agrees that upon receipt of the Purchase Price, the Note shall be cancelled and the Company shall have no further obligation to the Holder thereunder.

2. Representations and Warranties of the Holder. The Holder hereby represents and warrants to the Company with respect to the Note issued to such Holder that:

2.1 Ownership of Note. The Holder has, and at the Closing will have, good and marketable right, title and interest (legal and beneficial) in and to the Note, free and clear of all liens, pledges, security interests, charges, contractual obligations, claims or encumbrances of any kind. Upon payment for the Note in accordance with this Agreement, the Holder will convey the Note to the Company free and clear of all liens, pledges, security interests, charges, contractual obligations, claims or encumbrances of any kind.

2.2 Organization; Authorization. The Holder has full power and authority to enter into this Agreement. The execution, delivery and performance by the Holder of this Agreement has been duly authorized by all requisite action by the Holder and this Agreement constitutes a valid and binding obligation of the Holder, enforceable against the Holder in accordance with its terms, except as enforcement may be limited by general principles of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally.

2.3 No Consent Required. No consent, authorization, approval, order, license, certificate or permit or act of or from, or declaration or filing with, any foreign, federal, state, local or other governmental authority or regulatory body or any court or other tribunal or any party to any contract, agreement, instrument, lease or license to which the Holder is a party, is required for the execution, delivery or performance by the Holder of this Agreement or any of the other agreements, instruments and documents being or to be executed and delivered hereunder or in connection herewith or for the consummation of the transactions contemplated hereby.

2.4 Disclosure of Information. The Holder has received all the information it considers necessary or appropriate to determine whether to sell the Note to the Company pursuant to this Agreement. The Holder acknowledges (i) the Company has not made any representation or warranty, express or implied, except as set forth herein, regarding any aspect of the sale and purchase of the Note, the operation or financial condition of the Company or the value of the Note, (ii) that it is not relying upon the Company in making its decision to sell the Note to the Company pursuant to this Agreement and (iii) that the Company is relying upon the truth of the representations and warranties in this Section 2 in connection with the purchase of the Note hereunder.

2.5 Tax Consequences. The Holder has had an opportunity to review the federal, state and local tax consequences of the sale of the Note to the Company and the transactions contemplated by this Agreement with its own tax advisors. The Holder is relying solely on such advisors and not on any statements or representations of the Company.

2.6 No Conflict. Neither the execution and delivery of this Agreement or the consummation of any of the transactions contemplated hereby nor compliance with or fulfillment of the terms, conditions and provisions hereof or thereof will conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default (with or without notice or lapse of time, or both), or an event creating rights of acceleration, termination or cancellation or a loss of rights under (i) any material note, instrument, agreement, mortgage, lease, license, franchise, permit or other authorization, right, restriction or obligation to which the Holder is a party or by which the Holder or any of its properties is bound, (ii) any judgment or decree applicable to, or affecting, the Holder or (iii) any statute, law or rule to which the Holder is subject.

-2-

2.7 No Solicitation. The Holder has made no general solicitation in connection with the sale of the Note, acknowledges that it independently approached the Company regarding the transactions contemplated hereby and that the Company did not initiate or attempt to initiate the transactions contemplated hereby.

3. Representations and Warranties of the Company. The Company hereby represents and warrants to the Holder that:

3.1 Organization; Authorization. The Company has full power and authority to enter into this Agreement. The execution, delivery and performance by the Company of this Agreement has been duly authorized by all requisite action by the Company and this Agreement constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement may be limited by general principles of equity and by bankruptcy, insolvency and similar laws affecting creditors’ rights and remedies generally.

3.2 No Consent Required. No consent, authorization, approval, order, license, certificate or permit or act of or from, or declaration or filing with, any foreign, federal, state, local or other governmental authority or regulatory body or any court or other tribunal or any party to any contract, agreement, instrument, lease or license to which the Company is a party, is required for the execution, delivery or performance by the Company of this Agreement or any of the other agreements, instruments and documents being or to be executed and delivered hereunder or in connection herewith or for the consummation of the transactions contemplated hereby.

3.3 No Conflict. Neither the execution and delivery of this Agreement or the consummation of any of the transactions contemplated hereby nor compliance with or fulfillment of the terms, conditions and provisions hereof or thereof will conflict with, result in a breach of the terms, conditions or provisions of, or constitute a default (with or without notice or lapse of time, or both), or an event creating rights of acceleration, termination or cancellation or a loss of rights under (i) any material note, instrument, agreement, mortgage, lease, license, franchise, permit or other authorization, right, restriction or obligation to which the Company is a party or by which the Company or any of its properties is bound, (ii) any judgment or decree applicable to, or affecting, the Company or (iii) any statute, law or rule to which the Company is subject.

3.4 No Litigation. There is no action, suit, proceeding, judgment, claim or investigation pending or, to the knowledge of the Company, threatened against the Company which could reasonably be expected in any manner to challenge or seek to prevent, enjoin, alter or materially delay any of the transactions contemplated by this Agreement.

4. Securities Act; Transfer Restrictions. The Company hereby acknowledges that the (i) securities are not registered pursuant to the Securities Act of 1933, as amended, and (ii) the Note and the common stock underlying the Note may only be disposed of in compliance with Federal and State securities laws.

-3-

5. Miscellaneous.

5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York, without regard to its choice of law provisions. The parties hereto hereby agree that any action brought under this Agreement or related to the transactions contemplated hereby shall be brought in a Federal or State court located in the County of San Francisco in the State of California.

5.2 Counterparts. This Agreement may be executed in two or more counterparts and by facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

5.3 Publicity. The Holder will use reasonable commercial efforts to keep the terms and existence of this transaction confidential, provided that the Holder may share the details of this transaction in confidence with its attorneys, investors and financial and tax advisors, and may advise other potential purchasers of the Note that the Note has been repurchased by the Company. The Holder shall not be prohibited from referring communications with any other party regarding the transactions contemplated hereby to the Company.

5.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

5.5 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during the normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid or (iv) one (1) day after deposit with a nationally-recognized overnight courier, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 5.5).

5.6 Amendment and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of Holder and the Company.

5.7 Further Assurances. Each party hereby agrees to execute any additional documents and take any additional actions as may be reasonably necessary to carry out the terms of this Agreement.

5.8 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

-4-

5.9 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein.

[signature page follows]

-5-

IN WITNESS WHEREOF, the Holder and the Company have executed this Agreement effective as of the date and year first above written.

GUGGENHEIM PORTFOLIO COMPANY XXXI, LLC

By:	/s/ Jonathan Wood
	Name:	Guggenheim Portfolio Company XXXI, LLC
	Title:	Guggenheim Advisors, LLC
		Whitebox Advisors LLC
		Jonathan Wood, Chief Operating Officer

Address for notices:

Guggenheim Portfolio Company, XXXI, LLC
3033 Excelsior Blvd, Suite 300
Minneapolis, MN 55416

Phone No: 612-253-6001
Facsimile No.: 612-253-6151

VAXGEN, INC.

By:	/s/ James P. Panek          7/3/08
	Name:	James P. Panek
	Title:	President and Chief Executive Officer

Address for notices:

VaxGen, Inc.
349 Oyster Point Boulevard
South San Francisco, CA 94080
Attn: Mr. James Panek
Facsimile No.: (650) 624-4785

-6-

SCHEDULE A

Title of Securities: 5 1/2% Convertible Senior Subordinated Notes due April 1 2010 (the “Notes”)

Principal Amount of Notes: $650,000

Purchase Price: $533,000 ($820 for each $1,000 principal amount of Notes), plus accrued and unpaid interest thereon to the Settlement Date.

Accrued Interest: $9,633.07 plus an additional $99.31 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties.

Aggregate Purchase Price: $542,633.07 plus an additional $99.31 per day in the event that the Settlement Date is extended to a later date by mutual agreement of the parties.

Settlement Date: July 8, 2008

-7-